These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 1687299)

  • 21. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias.
    Atarashi H; Kuruma A; Yashima M; Saitoh H; Ino T; Endoh Y; Hayakawa H
    Clin Pharmacol Ther; 2000 Aug; 68(2):143-50. PubMed ID: 10976545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between pharmacological response, kinetics of plasma concentration and in vitro receptor affinities exemplified with beta-adrenoceptor blocking drugs.
    Wellstein A; Palm D
    Methods Find Exp Clin Pharmacol; 1984 Oct; 6(10):641-4. PubMed ID: 6151037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxicokinetics of a single intravenous dose of rac-propranolol versus optically pure propranolol in the rat.
    Bode W; Toet AE; Stolker AA; van Ginkel LA; Groen K; Wemer J; de Wildt DJ
    Chirality; 1995; 7(8):626-31. PubMed ID: 8593256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans.
    Kiriyama A; Honbo A; Iga K
    Int J Pharm; 2008 Feb; 349(1-2):53-60. PubMed ID: 17765415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronopharmacological aspects of PK/PD modelling.
    Lemmer B
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):458-64. PubMed ID: 9352396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A primer on pharmacokinetics.
    Quan DJ
    Nephrol Nurs J; 2008; 35(2):213-5. PubMed ID: 18472692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative pharmacokinetics of two brands of atenolol following a single oral administration.
    Irshaid YM; Rawashdeh NM; Awwadi FF; Kato MK
    Int J Clin Pharmacol Ther; 1996 Oct; 34(10):457-61. PubMed ID: 8897086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacokinetics of beta blockers in hyperthyroidism. Therapeutic relevance].
    Bouvier N; Millart H
    Therapie; 1998; 53(6):523-31. PubMed ID: 10070229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In silico optimization of pharmacokinetic properties and receptor binding affinity simultaneously: a 'parallel progression approach to drug design' applied to β-blockers.
    Advani P; Joseph B; Ambre P; Pissurlenkar R; Khedkar V; Iyer K; Gabhe S; Iyer RP; Coutinho E
    J Biomol Struct Dyn; 2016; 34(2):384-98. PubMed ID: 25854164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
    Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
    J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics and onset of action of esmolol in anesthetized dogs.
    Quon CY; Gorczynski RJ
    J Pharmacol Exp Ther; 1986 Jun; 237(3):912-8. PubMed ID: 2872328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers.
    Pauwels PJ; Gommeren W; Van Lommen G; Janssen PA; Leysen JE
    Mol Pharmacol; 1988 Dec; 34(6):843-51. PubMed ID: 2462161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Multimorbidity and pharmacotherapy in the elderly].
    Platt D
    Internist (Berl); 1991 Aug; 32(8):460-6. PubMed ID: 1938266
    [No Abstract]   [Full Text] [Related]  

  • 34. Coexistence of beta-1 and beta-2 adrenergic receptors in the human heart: effects of treatment with receptor antagonists or calcium entry blockers.
    Hedberg A; Kempf F; Josephson ME; Molinoff PB
    J Pharmacol Exp Ther; 1985 Sep; 234(3):561-8. PubMed ID: 2863366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
    Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
    Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Does the elimination of medication interest the physician?].
    Singlas E
    Sem Hop; 1981 Oct 18-25; 57(39-40):1648-52. PubMed ID: 6119792
    [No Abstract]   [Full Text] [Related]  

  • 37. [The rational selection of beta-blockers in the treatment of hypertension].
    Ter Arkh; 1999; 71(2):57-64. PubMed ID: 10222557
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacology of beta-blockers: classical aspects and recent developments.
    Haeusler G
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S1-9. PubMed ID: 11527109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of pharmacological properties of a group of beta-blocker agents by molecular topology.
    Garcia-March FJ; Cercós-Del-Pozo RA; Pérez-Giménez F; Salabert-Salvador MT; Jaén-Oltra J; Antón-Fos GM
    J Pharm Pharmacol; 1995 Mar; 47(3):232-6. PubMed ID: 7602487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological distribution diagrams: a tool for de novo drug design.
    Gálvez J; García-Domenech R; de Gregorio Alapont C; de Julián-Ortiz JV; Popa L
    J Mol Graph; 1996 Oct; 14(5):272-6. PubMed ID: 9097233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.